The global cell dissociation market in terms of revenue was estimated to be worth $0.6 billion in 2023 and is poised to reach $1.4 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028.
Download PDF Brochure:
Cell dissociation Market Dynamics
Driver: Increase in recombinant therapeutics sourced from mammalian cells
The biopharmaceutical industry has witnessed a considerable increase in the proportion of recombinant therapeutics sourced from mammalian cells since 2002. The number of approved recombinant products from mammalian cell culture increased by 8.5% annually from 2002 to 2022. As of June 2022, more than 300 recombinant products have been commercialized, indicating a rapid shift towards mammalian-based therapeutics, which nearly account for 67% of therapeutics in 2022. .Cell culture products, including cell dissociation form an integral part of developing mammalian-based recombinant therapeutics, propelling the industry growth.
Restraint: High cost of cell-based research
Isolation and purification of cell organelles integrates expensive products, additionally, automated/sem-automated benchtop instruments are more expensive than traditional methods. Despite significant benefits offered by automated instruments, high costs associated with these instruments may limit the adoption of products further restraining the market growth.
Opportunity: Advancements in non-enzymatic tissue dissociation
Companies operating in the market are introducing innovative and advanced products to overcome competition and generate more revenue. Most researchers in R&D institutes and biotechnology companies have primarily relied on traditional enzymatic dissociation products to separate cells from primary tissues. Although these traditional enzymatic dissociation products have advantages, such as better dissociation while performing research, they can sometimes be cytotoxic and damage viable cells. To overcome this issue and differentiate their product offerings, several companies are introducing non-enzymatic products that are non-cytotoxic. Owing to this advantage, the demand for non-enzymatic dissociation products is increasing among several end users.
Challenge: Limitations associated with dissociated cell culture
The key limitation of dissociated cultures is the small number of cells relative to immortalized cell lines. This makes it difficult to perform biochemical experiments requiring a high starting material volume. Additionally, most primary cell cultures are not homogeneous, which poses a challenging scenario for cell dissociation experiments. Neuronal cultures are often mixtures of both glia and neurons that respond to different neurotransmitters, so identifying an individual population of cells can be difficult.
North America dominates the global cell dissociation market
The cell dissociation market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2022, North America accounted for the largest share in the cell dissociation market, which is attributed to increasing investments in the development of novel cell-based therapies.
The cell dissociation market is moderately consolidated in nature with prominent market players such as Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Corning Incorporated (US), Becton, Dickinson and Company (US), STEMCELL Technologies (Canada), PromoCell GmbH (Germany), Miltenyi Biotec (Germany), ATCC (US), HiMedia Laboratories (India), PAN-Biotech (Germany), CellSystems GmbH (Germany), AMSBIO (England), Neuromics (US), VitaCyte, LLC. (US), ALSTEM (US), Biological Industries (Israel), Gemini Bio (US), Innovative Cell Technologies, Inc. (US), Central Drug House (P) Ltd. (India), Worthington Biochemical Corporation (US), Capricorn Scientific (Germany), Abeomics (US), and Genlantis, Inc. (US).
Recent Development of Cell Dissociation Industry
In 2020, Miltenyi Biotec launched automated and closed adherent cell culture solutions on CliniMACS Prodigy.
In 2020, Merck The company expanded its Life Sciences production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire (US).
In 2020, STEMCELL Technologies partnered with CollPlant to secure CollPlant rhCollagen for STEMCELL’s use in cell culture applications.
In 2021, Danaher (Cytiva) partnered with Diamyd Medical, wherein Diamyd selected Cytiva’s FlexFactory platform for making precision medicine type-1 diabetes vaccines.
In 2021, Danaher (Cytiva) collaborated with the Government of Telangana (India) to strengthen the biopharma industry in India with new labs.
Cell Dissociation Market Advantages:
Increased Efficiency: Cell dissociation reagents provide a more efficient and reliable method for dissociating cell samples, which can significantly reduce processing time and improve the quality of the results.
Higher Yields: Cell dissociation reagents are designed to maximize cell yield, allowing for more effective downstream applications such as flow cytometry and immunological assays.
Improved Quality: Cell dissociation reagents help to ensure that cells are undamaged during the isolation process, thereby resulting in higher quality samples.
Cost Effective: Cell dissociation reagents provide a cost-effective solution, as they are typically less expensive than traditional methods.
Greater Flexibility: Cell dissociation reagents offer greater flexibility in terms of the types of cells that can be isolated, allowing for a wider range of downstream applications.
Related links:
Comments